Eli Lilly Demonstrates Revenue Growth Beyond GLP-1 Weight Loss Drugs
Eli Lilly (LLY) reported strong third-quarter results, driven significantly by its GLP-1 portfolio. Zepbound and Mounjaro accounted for 66% of the company's $24.4 billion total revenue, with Zepbound growing 49% year-over-year and Mounjaro increasing 65%. Despite this dominance in the obesity and diabetes sectors, the company is successfully diversifying its revenue streams through other therapeutic areas. Key growth drivers outside of weight loss include Kisunla for Alzheimer's disease, Jaypirca for cancer, and immunology therapies Ebglyss and Omvoh. These products have shown significant year-over-year revenue increases, ranging from 59% to 175%. Recent label expansions for these drugs are expected to expand their addressable markets and contribute meaningfully to medium-term sales growth.
Coverage
- Eli Lilly, Novo weight-loss drugs to get rare vision loss warning
- Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
- Eli Lilly Demonstrates Revenue Growth Beyond GLP-1 Weight Loss Drugs
- Cloudflare’s stock mounts a big comeback after fastest sales surge in nearly 4 years
- Nano Dimension Reports Q3 Revenue Growth to $31.9 Million Driven by Markforged and Essemtec
- Toyota stock rallies after company lowered sales guidance. Here’s how rare that is.
- Dave stock slumps as Q3 profit trails estimates regardless of higher revenue, raised guidance
- Eli Lilly Shares Surge Toward Record Highs on Strong GLP-1 Drug Demand
- Eli Lilly Reports 39% Revenue Growth Driven by GLP-1 Drugs Amid High Valuation
- Eli Lilly Reports 39% Revenue Growth Driven by Increased Sales Volume